Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ELUT | Elutia Inc

Index- P/E- EPS (ttm)-2.25 Insider Own63.15% Shs Outstand11.82M Perf Week1.42%
Market Cap23.24M Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float5.99M Perf Month-5.92%
Income-33.95M PEG- EPS next Q-0.55 Inst Own18.48% Short Float / Ratio2.15% / 0.30 Perf Quarter-39.41%
Sales48.40M P/S0.48 EPS this Y13.87% Inst Trans-0.12% Short Interest0.13M Perf Half Y-12.27%
Book/sh-1.36 P/B- EPS next Y32.93% ROA-64.54% Target Price12.00 Perf Year-78.81%
Cash/sh0.57 P/C2.50 EPS next 5Y- ROE-775.14% 52W Range1.10 - 9.01 Perf YTD-66.35%
Dividend- P/FCF- EPS past 5Y-21.70% ROI-372.57% 52W High-84.13% Beta-0.04
Dividend %- Quick Ratio0.63 Sales past 5Y6.05% Gross Margin35.86% 52W Low30.00% ATR0.21
Employees164 Current Ratio0.84 Sales Q/Q-18.53% Oper. Margin-49.98% RSI (14)50.21 Volatility13.73% 16.44%
OptionableNo Debt/Eq- EPS Q/Q5.13% Profit Margin-70.13% Rel Volume0.14 Prev Close1.36
ShortableYes LT Debt/Eq- EarningsAug 14 AMC Payout- Avg Volume429.46K Price1.43
Recom1.00 SMA205.60% SMA50-11.33% SMA200-46.07% Volume58,339 Change5.15%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
08:30AM Loading…
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:17AM Loading…
May-13-23 08:17AM
May-11-23 09:58AM
May-10-23 04:05PM
May-03-23 04:05PM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
Mar-20-23 12:01PM
04:05PM Loading…
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
Nov-07-22 04:05PM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
May-02-22 08:21AM
Apr-25-22 04:05PM
Apr-12-22 04:05PM
Apr-04-22 08:00AM
Mar-31-22 06:50PM
Mar-11-22 08:30AM
Mar-07-22 06:40AM
Mar-04-22 09:28AM
Mar-03-22 06:25PM
Feb-23-22 04:01PM
Feb-17-22 04:01PM
Feb-14-22 12:00PM
Jan-18-22 08:45AM
Jan-11-22 10:00AM
Dec-27-21 04:01PM
Dec-08-21 05:31PM
Dec-06-21 06:59AM
Nov-15-21 04:05PM
Nov-09-21 05:25PM
Nov-02-21 03:02PM
Oct-26-21 08:30AM
Oct-25-21 04:01PM
Sep-15-21 04:05PM
Aug-31-21 04:05PM
Aug-15-21 03:05AM
Aug-09-21 04:01PM
Jul-26-21 04:01PM
Jun-30-21 09:34AM
Jun-10-21 01:30AM
Jun-07-21 08:00AM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mills C RandalPRESIDENT AND CEOApr 27Option Exercise0.0044,947048,008Apr 28 05:31 PM
Birchview Capital, LP10% OwnerMar 27Buy1.5910,00015,8701,655,184Mar 27 04:17 PM
Birchview Capital, LP10% OwnerMar 24Buy1.3520,00027,0781,645,184Mar 27 04:17 PM
Birchview Capital, LP10% OwnerMar 23Buy1.49110,000164,0101,625,184Mar 27 04:17 PM
Englese ThomasCHIEF COMMERCIAL OFFICERMar 09Sale4.302891,24317,917Mar 09 09:18 PM
Englese ThomasCHIEF COMMERCIAL OFFICERMar 08Option Exercise0.00937018,206Mar 09 09:18 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08Option Exercise0.001,287046,504Mar 09 09:11 PM
Colpman DavidDirectorDec 15Buy3.903,09812,0823,098Dec 16 04:46 PM
Makes BrigidDirectorDec 09Buy3.652,0007,3002,000Dec 12 05:08 PM
Birchview Capital, LP10% OwnerDec 08Buy3.7913,06149,5181,515,184Feb 13 07:01 PM
Birchview Capital, LP10% OwnerDec 07Buy3.5844,000157,5201,502,123Feb 13 07:01 PM
HighCape Capital, L.P.DirectorDec 05Buy4.75735,0003,491,2505,597,604Dec 07 04:31 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERDec 05Buy4.6522,000102,22045,217Dec 05 08:44 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERDec 02Buy4.036,00024,18023,217Dec 05 08:44 PM
Birchview Capital, LP10% OwnerDec 01Buy4.7540,000190,0001,458,123Feb 13 07:01 PM